Search Results - "Maertens, Ophélia"

An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer by Maertens, Ophélia, Cichowski, Karen

“…The RAS pathway is one of the most commonly deregulated pathways in human cancer. Mutations in RAS genes occur in nearly 30% of all human tumors. However in…”
Get full text

Genetic modifiers of the BRD4-NUT dependency of NUT midline carcinoma uncovers a synergism between BETis and CDK4/6is by Liao, Sida, Maertens, Ophélia, Cichowski, Karen, Elledge, Stephen J

“…Bromodomain and extraterminal (BET) domain inhibitors (BETis) show efficacy on NUT midline carcinoma (NMC). However, not all NMC patients respond, and…”
Get full text

Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy by Montero, Joan, Sarosiek, Kristopher A., DeAngelo, Joseph D., Maertens, Ophélia, Ryan, Jeremy, Ercan, Dalia, Piao, Huiying, Horowitz, Neil S., Berkowitz, Ross S., Matulonis, Ursula, Jänne, Pasi A., Amrein, Philip C., Cichowski, Karen, Drapkin, Ronny, Letai, Anthony

“…There is a lack of effective predictive biomarkers to precisely assign optimal therapy to cancer patients. While most efforts are directed at inferring drug…”
Get full text

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors by Malone, Clare F, Emerson, Chloe, Ingraham, Rachel, Barbosa, William, Guerra, Stephanie, Yoon, Haejin, Liu, Lin L, Michor, Franziska, Haigis, Marcia, Macleod, Kay F, Maertens, Ophélia, Cichowski, Karen

“…Although agents that inhibit specific oncogenic kinases have been successful in a subset of cancers, there are currently few treatment options for malignancies…”
Get more information

Elucidating distinct roles for NF1 in melanomagenesis by Maertens, Ophélia, Johnson, Bryan, Hollstein, Pablo, Frederick, Dennie T, Cooper, Zachary A, Messiaen, Ludwine, Bronson, Roderick T, McMahon, Martin, Granter, Scott, Flaherty, Keith, Wargo, Jennifer A, Marais, Richard, Cichowski, Karen

“…BRAF mutations play a well-established role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by…”
Get more information

Exploiting Cancer Cell Vulnerabilities to Develop a Combination Therapy for Ras-Driven Tumors by De Raedt, Thomas, Walton, Zandra, Yecies, Jessica L., Li, Danan, Chen, Yimei, Malone, Clare F., Maertens, Ophélia, Jeong, Seung Min, Bronson, Roderick T., Lebleu, Valerie, Kalluri, Raghu, Normant, Emmanuel, Haigis, Marcia C., Manning, Brendan D., Wong, Kwok-Kin, Macleod, Kay F., Cichowski, Karen

“…Ras-driven tumors are often refractory to conventional therapies. Here we identify a promising targeted therapeutic strategy for two Ras-driven cancers:…”
Get full text

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors by Ercan, Dalia, Xu, Chunxiao, Yanagita, Masahiko, Monast, Calixte S, Pratilas, Christine A, Montero, Joan, Butaney, Mohit, Shimamura, Takeshi, Sholl, Lynette, Ivanova, Elena V, Tadi, Madhavi, Rogers, Andrew, Repellin, Claire, Capelletti, Marzia, Maertens, Ophélia, Goetz, Eva M, Letai, Anthony, Garraway, Levi A, Lazzara, Matthew J, Rosen, Neal, Gray, Nathanael S, Wong, Kwok-Kin, Jänne, Pasi A

“…The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR…”
Get more information

A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers by Guerra, Stephanie L., Maertens, Ophélia, Kuzmickas, Ryan, De Raedt, Thomas, Adeyemi, Richard O., Guild, Caroline J., Guillemette, Shawna, Redig, Amanda J., Chambers, Emily S., Xu, Man, Tiv, Hong, Santagata, Sandro, Jänne, Pasi A., Elledge, Stephen J., Cichowski, Karen

“…While KRAS mutations are common in non-small cell lung cancer (NSCLC), effective treatments are lacking. Here, we report that half of KRAS-mutant NSCLCs…”
Get full text

Glomus Tumors in Neurofibromatosis Type 1: Genetic, Functional, and Clinical Evidence of a Novel Association by BREMS, Hilde, PARK, Caroline, SLOAN, Jennifer L, YAO, Lawrence, LEE, Chyi-Chia Richard, SCIOT, Raf, DE SMET, Luc, LEGIUS, Eric, STEWART, Douglas R, MAERTENS, Ophélia, PEMOV, Alexander, MESSIA, Ludwine, UPADHYAYA, Meena, CLAES, Kathleen, BEERT, Eline, PEETERS, Kristel, MAUTNER, Victor

“…Neurofibromatosis type 1 (NF1) is a common disorder that arises secondary to mutations in the tumor suppressor gene NF1. Glomus tumors are small, benign but…”
Get full text

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant Melanomas by Maertens, Ophélia, Kuzmickas, Ryan, Manchester, Haley E, Emerson, Chloe E, Gavin, Alessandra G, Guild, Caroline J, Wong, Terence C, De Raedt, Thomas, Bowman-Colin, Christian, Hatchi, Elodie, Garraway, Levi A, Flaherty, Keith T, Pathania, Shailja, Elledge, Stephen J, Cichowski, Karen

“…Although the majority of -mutant melanomas respond to BRAF/MEK inhibitors, these agents are not typically curative. Moreover, they are largely ineffective in -…”
Get more information

Paths of resistance to EGFR inhibitors: is NF enough? by Maertens, Ophélia, Cichowski, Karen

“…Although the majority of patients with EGFR-mutant lung cancer respond well to EGF receptor (EGFR) tyrosine kinase inhibitors (TKI), all patients eventually…”
Get more information

A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies by Maertens, Ophélia, McCurrach, Mila E, Braun, Benjamin S, De Raedt, Thomas, Epstein, Inbal, Huang, Tannie Q, Lauchle, Jennifer O, Lee, Hyerim, Wu, Jianqiang, Cripe, Timothy P, Clapp, D Wade, Ratner, Nancy, Shannon, Kevin, Cichowski, Karen

“…Preclinical studies using genetically engineered mouse models (GEMM) have the potential to expedite the development of effective new therapies; however, they…”
Get full text

Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients by Maertens, Ophélia, Prenen, Hans, Debiec-Rychter, Maria, Wozniak, Agnieszka, Sciot, Raf, Pauwels, Patrick, De Wever, Ivo, Vermeesch, Joris R., de Raedt, Thomas, De Paepe, Anne, Speleman, Frank, van Oosterom, Allan, Messiaen, Ludwine, Legius, Eric

“…Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. KIT and PDGFRA activating mutations are the…”
Get full text

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023) by De Raedt, Thomas, Chawla, Sant, Van Tine, Brian A., O’Sullivan, Geraldine, Chen, Alice, Cichowski, Karen, Widemann, Brigitte C., Wolters, Pamela L., Basu, Mitali, Perentesis, John, Maertens, Ophélia, Reinke, Denise, Okuno, Scott H., Lu, Yao, Kim, AeRang, Chugh, Rashmi

“…Purpose. Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive soft tissue sarcomas. Combining Hsp90 inhibitors to enhance endoplasmic reticulum…”
Get full text

Mutations in RABL3 alter KRAS prenylation and are associated with hereditary pancreatic cancer by Nissim, Sahar, Leshchiner, Ignaty, Mancias, Joseph D., Greenblatt, Matthew B., Maertens, Ophélia, Cassa, Christopher A., Rosenfeld, Jill A., Cox, Andrew G., Hedgepeth, John, Wucherpfennig, Julia I., Kim, Andrew J., Henderson, Jake E., Gonyo, Patrick, Brandt, Anthony, Lorimer, Ellen, Unger, Bethany, Prokop, Jeremy W., Heidel, Jerry R., Wang, Xiao-Xu, Ukaegbu, Chinedu I., Jennings, Benjamin C., Paulo, Joao A., Gableske, Sebastian, Fierke, Carol A., Getz, Gad, Sunyaev, Shamil R., Wade Harper, J., Cichowski, Karen, Kimmelman, Alec C., Houvras, Yariv, Syngal, Sapna, Williams, Carol, Goessling, Wolfram

“…Pancreatic ductal adenocarcinoma is an aggressive cancer with limited treatment options 1 . Approximately 10% of cases exhibit familial predisposition, but…”
Get full text

Defining key signaling nodes and therapeutic biomarkers in NF1-mutant cancers by Malone, Clare F, Fromm, Jody A, Maertens, Ophélia, DeRaedt, Thomas, Ingraham, Rachel, Cichowski, Karen

“…NF1 encodes a RAS GTPase-activating protein. Accordingly, aberrant RAS activation underlies the pathogenesis of NF1-mutant cancers. Nevertheless, it is unclear…”
Get more information

Molecular Dissection of Isolated Disease Features in Mosaic Neurofibromatosis Type 1 by Maertens, Ophélia, De Schepper, Sofie, Vandesompele, Jo, Brems, Hilde, Heyns, Ine, Janssens, Sandra, Speleman, Frank, Legius, Eric, Messiaen, Ludwine

“…Elucidation of the biological framework underlying the development of neurofibromatosis type 1 (NF1)–related symptoms has proved to be difficult. Complicating…”
Get full text

Gonadal and gonadosomatic mosaicism in NF1: report of two families by Seidl‐Philipp, Magdalena, Veyt, Nathalie, Schnaiter, Simon, Krogsdam, Anne, Schwendinger, Simon, Maertens, Ophélia, Fauth, Christine, Schmuth, Matthias, Legius, Eric, Wimmer, Katharina, Brems, Hilde

Get full text

Somatic Mutation Analysis in NF1 Café au lait Spots Reveals Two NF1 Hits in the Melanocytes by De Schepper, Sofie, Maertens, Ophélia, Callens, Tom, Naeyaert, Jean-Marie, Lambert, Jo, Messiaen, Ludwine

Get full text

Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers by Lock, Rebecca, Ingraham, Rachel, Maertens, Ophélia, Miller, Abigail L, Weledji, Nelly, Legius, Eric, Konicek, Bruce M, Yan, Sau-Chi B, Graff, Jeremy R, Cichowski, Karen

“…Neurofibromin 1-mutant (NF1-mutant) cancers are driven by excessive Ras signaling; however, there are currently no effective therapies for these or other…”
Get full text